Patents by Inventor John L. Haslam

John L. Haslam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9968553
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 15, 2018
    Assignees: SILVERGATE PHARMACAUTICALS, INC., UNIVERSITY OF KANSAS
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Publication number: 20180116954
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Inventors: Lian G. RAJEWSKI, Roger A. RAJEWSKI, John L. HASLAM, Kathleen HEPPERT, Michael C. BECKLOFF, Frank SEGRAVE, Robert MAURO, Peter COLABUONO
  • Patent number: 9855214
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 2, 2018
    Assignees: SILVERGATE PHARMACEUTICALS, INC, UNIVERSITY OF KANSAS
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Publication number: 20170181968
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 29, 2017
    Inventors: Lian G. RAJEWSKI, Roger A. RAJEWSKI, John L. HASLAM, Kathleen HEPPERT, Michael C. BECKLOFF, Frank SEGRAVE, Robert MAURO, Peter COLABUONO
  • Publication number: 20150258027
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: October 2, 2013
    Publication date: September 17, 2015
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Patent number: 8900629
    Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 2, 2014
    Assignee: University of Kansas
    Inventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam
  • Patent number: 8778366
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 15, 2014
    Assignees: University of Kanasas, Silvergate Pharmaceuticals, Inc.
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Publication number: 20140100260
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: June 10, 2013
    Publication date: April 10, 2014
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Patent number: 8568747
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: October 29, 2013
    Assignees: Silvergate Pharmaceuticals, Inc., University of Kansas
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Seagrave, Robert Mauro, Peter Colabuono
  • Publication number: 20130005831
    Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.
    Type: Application
    Filed: December 22, 2011
    Publication date: January 3, 2013
    Applicant: UNIVERSITY OF KANSAS
    Inventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam
  • Patent number: 8105625
    Abstract: The present invention provides an orally dissolving capsule comprising pullulan, a plasticizer and a dissolution enhancing agent.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: January 31, 2012
    Assignee: University of Kansas
    Inventors: Roger A. Rajewski, John L. Haslam
  • Publication number: 20100047343
    Abstract: A multi-particulate pharmaceutical composition of rapid release particles and controlled release particles comprising tramadol or a salt thereof is provided. The composition provides a rapid and controlled release of tramadol or a salt thereof in a substantially pH independent manner after oral administration to a subject. The composition can be included in a capsule, caplet, sachet, or other solid dosage form adapted to retain and then release solid pharmaceutical compositions.
    Type: Application
    Filed: October 29, 2009
    Publication date: February 25, 2010
    Applicant: The University of Kansas
    Inventors: John L. Haslam, Roger A. Rajewski
  • Publication number: 20080248102
    Abstract: The present invention provides an orally dissolving capsule comprising pullulan, a plasticizer and a dissolution enhancing agent.
    Type: Application
    Filed: April 4, 2008
    Publication date: October 9, 2008
    Applicant: University of Kansas
    Inventors: Roger A. Rajewski, John L. Haslam
  • Patent number: 7235258
    Abstract: Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which are ameliorated by effecting a modulation of CNS activity. The ability of the compositions to sustain relatively constant levels of the drug at a therapeutic dose in the serum for extended periods of time enables a once or twice daily administration schedule.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: June 26, 2007
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: David S. Wells, Lian G. Rajewski, Thomas B. Marriott, James D. Pipkin, John L. Haslam
  • Patent number: 4886668
    Abstract: The instant invention is directed to a multiparticulate osmotic pump, for the controlled release of diltiazem L-malate to an environment of use, said pump comprising:(I) a carrier medium which does not maintain its integrity in the environment of use;(II) a multiple of tiny osmotic pump elements each comprising:(A) a core comprises diltiazem L-malate and an effective buffering amount of sodium bitartrate surrounded by(B) a rate controlling water insoluble wall, having a fluid permeability of 6.96.times.10.sup.-18 to 6.96.times.10.sup.-14 cm.sup.3 sec/g and a reflection coefficient of less than 0.5, prepared from:(i) a polymer permeable to water but impermeable to solute and(ii) 0.1 to 60% by weight, based on the total weight of (i) and (ii), of at least one pH insensitive pore forming additive dispersed throughout said wall,wherein the total amount of diltiazem L-malate in all of the osmotic pump elements is a therapeutically effective amount.
    Type: Grant
    Filed: September 24, 1987
    Date of Patent: December 12, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John L. Haslam, Gerald S. Rork
  • Patent number: 4880631
    Abstract: The instant invention is directed to an osmotic pump, for the controlled release of diltiazem L-malate to an environment of use, said pump comprising:(A) a core which comprises a therapeutically effective amount of diltiazem L-malate and an effective buffering amount of sodium bitartrate surrounded by(B) a rate controlling water insoluble wall, having a fluid permeability of 6.96.times.10.sup.-18 to 6.96.times.10.sup.-14 cm.sup.3 sec/g and a reflection coefficient of less than 0.5, prepared from:(i) a polymer permeable to water but impermeable to solute and(ii) 0.1 to 60% by weight, based on the total weight of (i) and (ii), of at least one pH insensitive pore forming additive dispersed throughout said wall.
    Type: Grant
    Filed: September 24, 1987
    Date of Patent: November 14, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John L. Haslam, Gerald S. Rork
  • Patent number: 4573982
    Abstract: This invention relates to an eyeglass frame mounted unit dose ophthalmic drug delivery device. A unit dose of ophthalmic medicament is provided by either a preloaded disposable microsyringe, preloaded disposable tip or manually loaded calibrated microsyringe rigidly mounted on a block which itself is slidably mounted to the eyeglass frame. The device allows for the insertion of ophthalmic medication into the inferior cul de sac of the eye.
    Type: Grant
    Filed: November 10, 1983
    Date of Patent: March 4, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Alexander E. Forbes, John L. Haslam
  • Patent number: 4530928
    Abstract: This invention involves complexes of quinoline carboxylic acid derivatives with guanidine and guanidine carbonate. The complexes have a greater solubility and dissolution rate when compared to the parent quinoline carboxylic acid derivatives and thus are more effective anti bacterials than the parent acids.
    Type: Grant
    Filed: December 22, 1982
    Date of Patent: July 23, 1985
    Assignee: Merck & Co., Inc.
    Inventors: John L. Haslam, Stefano A. Pogany
  • Patent number: 4478822
    Abstract: This invention relates to a unique drug delivery system for delivering drugs to a body cavity. The drug delivery system comprises a medicament and a polymer such that the drug delivery system is a liquid at room temperature but forms a semi-solid or gel at the body temperature in the body cavity.
    Type: Grant
    Filed: May 16, 1983
    Date of Patent: October 23, 1984
    Assignee: Merck & Co., Inc.
    Inventors: John L. Haslam, Takeru Higuchi, Arthur R. Mlodozeniec
  • Patent number: 4474751
    Abstract: This invention describes the application of selected polymers as novel drug delivery systems which use the body temperature and pH to induce a liquid to gel transition of the polymer which contains a drug or therapeutic agent therein. The goal of such a delivery system is to achieve a greater degree of bioavailability or sustained concentration of a drug.
    Type: Grant
    Filed: May 16, 1983
    Date of Patent: October 2, 1984
    Assignee: Merck & Co., Inc.
    Inventors: John L. Haslam, Takeru Higuchi, Arthur R. Mlodozeniec